Drug Profile
Research programme: AAV-based gene therapies - Bristol-Myers Squibb/uniQure
Alternative Names: AAV-S100A1; AMT 120; AMT-126; S100A1Latest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; uniQure
- Class Calcium binding proteins; Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders